Biotech Stocks

Should You Buy Amarin (AMRN) Stock? 4 Pros, 4 Cons

Year-to-date, Amarin (AMRN) stock is up nearly 20% due to Pfizer buyout chatter. According to rumors, the pharma giant is interested in making …

Spooked Investors Send ResMed (RMD) Stock Spiraling; Analysts Weigh In

Send ResMed (RMD) shares tanked nearly 18% today, leaving investors at odds over when it will hit a bottom. What’s causing investors to hit …

TherapeuticsMD (TXMD) Stock Has Triple-Digit Upside From Here, Says Analyst

TherapeuticsMD (TXMD) investors are keeping an eye on the pace of commercialization efforts for Imvexxy, Annovera, and Bijuva. That will prove critical for …

Amarin (AMRN): Management Is Flying in the Dark

A lot of Amarin (AMRN) stock bulls expected shares to fly up toward $30 following shockingly good results of the company’s Reduce-It cardiovascular …

The Clock Is Ticking on Aptinyx (APTX) Stock; Cowen Weighs In

Wednesday turned out to be a nightmare for Aptinyx (APTX) investors, as the stock price crashed nearly 70% in the wake of clinical …

Amarin (AMRN) Stock: This Bull Isn’t Bullish Enough

Amarin (AMRN) has been Wall Street’s biggest standout of 2018, with shares skyrocketing nearly 240%. The biggest question for investors, then, is whether …

Bullish Analyst Ups Price Target on Axsome (AXSM) Stock as It Gets Closer in Bringing MDD Drug to Market

Axsome Therapeutics (AXSM) stock more than doubled since the drug maker announced positive results for its phase 2 trial, ASCEND on Monday. The …

La Jolla (LJPC) Stock Crashes — Is There a Light at the End of the Tunnel?

La Jolla’s (LJPC) shares lost almost half of their value Monday, after the company pre-announced fourth quarter revenues for its drug Giapreza – …

Analyst Cuts Price Target on Aphria (APHA) Stock Amid Recent Takeover Talks

Aphria (APHA) stock has been experiencing some turbulence ever since a short report came out in early December suggesting the company was benefiting …

Why Does This Analyst Upgrade Bausch Health (BHC) Stock After Years of Distrust?

Bausch Health (BHC) is getting a bit of special treatment. Following a tough run of negative sentiment toward the company, Piper Jaffray analyst David Amsellem …